Norrin induced expression of genes and use thereof to treat disease
A method is provided to increase the expression of the genes CASP3 and THBD; and decrease the expression of the genes COL18A1, CPB2, NPR1, OCLN, BMP2, CLCL6, IL12B, SELPLG, CX3CL1, CASP3, THBD, COL18A1, CPB2, NPR1, CLDN5, CLD3, PIGF, BDNF, CNTF, VEGF-A, CAM-1, PGF, FOX-01, FOX-04, PDGFB, TGFA, HGF, VE-Cadherin, or PLAU. As a result, conditions associated with expression of these genes are treated. Caspase 3 is encoded by CASP3 (GenBank assembly accession: GCA_000001405.22) and cleaves and activates caspases 6 and 7; and the protein itself is processed and activated by caspases 8, 9, and 10. Caspase 3 is the predominant caspase involved in the cleavage of amyloid-beta 4A precursor protein, which is associated with neuronal death in Alzheimer's disease and after spinal cord injury. As caspase 3 is implicated in apoptosis upregulation of CASP3 can be used to induce dysfunction cell removal.
1 . A method of enhancing treatment of a microvascular barrier consisting of:
administering an anti-VEGF agent to the microvascular barrier as an adjunct therapeutic selected from the group consisting of bevacizumab ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, pazopanib, or a combination thereof;
exposing the microvascular barrier simultaneously to norrin; and
decreasing gene expression in endothelial cells of at least one gene of BMP2, CLCL6, IL12B, SELPLG, CX3CL1, COL18A1, CPB2, NPR1, CLDN5, CLD3, PIGF, BDNF, CNTF, VEGF-A, CAM-1, PGF, FOX-01, FOX-04, PDGFB, TGFA, HGF, VE-Cadherin, or PLAU with said norrin to simultaneously suppress VEGF binding, decrease production of vascular endothelial growth factor A, and stimulate tight junction and adherens junction protein expression in a cell of the microvascular barrier to prevent familial exudative vitreoretinopathy.
2 . The method of claim 1 wherein all of said genes are modulated by said norrin.
3 . The method of claim 1 , wherein the microvascular barrier is a retinal vessel in a subject.
4 . The method of claim 3 , wherein the exposing step is by intraocular injection.
5 . The method of claim 3 , wherein the exposing step is by systemic administration.
6 . The method of claim 3 , wherein said subject is human.
7 . The method of claim 3 , wherein said subject is one of: cow, horse, sheep, pig, goat, chicken, cat, dog, mouse, guinea pig, hamster, rabbit, rat, or a cell derived from one of the aforementioned.
8 . The method of claim 1 , wherein said norrin is a polypeptide of SEQ ID. NO. 2.
9 . The method of claim 1 , wherein said norrin is a fragment of SEQ ID. NO. 1 that binds a frizzled-4 receptor of the retinal vessel cells.
10 . The method of claim 1 , wherein said norrin is recombinant.